

1 November 2024

ASX Announcement

## Nasodine COVID-19 Patent Allowed in Mexico

---

- **Patent covers use of Nasodine to reduce shedding of SARS-CoV-2**
- **Now allowed or granted in US, Australia, South Africa and Mexico**

**Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company)** is pleased to announce that it has received notice of allowance in Mexico of its COVID-19 patent. This patent is already granted in US, Australia and South Africa, and applications in other countries are pending.

The patent specifically protects the use of Nasodine® Nasal Spray (“Nasodine”) and any other intranasal povidone-iodine (PVP-I) preparations as a method of reducing the viral load of SARS-CoV-2 in the nose. Granted claims also cover pre-exposure prophylaxis (preventative use prior to exposure) against SARS-CoV-2, notably in the case of healthcare workers.

This patent is supported by the published clinical trial (announcements 7 August 2023 and 2 April 2024), which showed that in COVID-19 subjects with early symptoms, the frequent use of Nasodine over three days resulted in 100% clearance of the virus from the nasal passages.

“This patent and the clinical trial are very relevant to the use of Nasodine as a nasal antiseptic,” said Dr Peter Molloy, Executive Chairman of Firebrick. “The elimination of viruses from the nose and especially pandemic viruses, is a key benefit of Nasodine.”

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine ([www.firebrickpharma.com](http://www.firebrickpharma.com)). The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray, and filed international trademarks and multiple patents on the product, including pharmaceutical formulation and use patents. The Company has also completed six clinical trials for the nasal spray, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

#### Media enquiries:

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

#### Investor enquiries:

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)